Valuations have compressed, rate expectations keep shifting and the S&P 500 now trades on a forward P/E that sits near levels usually seen around recessions. That mix can feel uncomfortable. It also creates a window where solid large caps with value traits can quietly reset. This article walks through three U.S. Large-Cap Value stocks exposed to these macro cross-currents and explains why some investors are watching them closely right now.
The examples in this article are just a small sample, and the full screen surfaced 20 more large caps with value traits and equally compelling narratives that are not covered here. To see the broader opportunity set, head straight into the U.S. Large-Cap Value Equities screener to identify, analyze and filter for your own highest conviction ideas.
First Solar (FSLR)
Overview: First Solar is a U.S. based solar technology company that designs and manufactures thin film photovoltaic modules for large scale power projects worldwide.
Operations: First Solar generates about US$5.4b in revenue from the design, manufacture and sale of cadmium telluride solar modules.
Market Cap: US$19.1b
First Solar fits the U.S. Large Cap Value Equities theme as a profitable, asset heavy solar manufacturer whose cyclical profile often leaves the valuation looking conservative relative to faster growing clean energy peers.
"Recent U.S. policy changes, specifically strengthened incentives and tighter restrictions against foreign entities of concern (such as China) under the new reconciliation legislation, are boosting First Solar's competitive moat, supporting robust demand for domestically produced modules, and enabling the company to capture higher long-term contracted pricing, directly improving forward revenue visibility and gross margins."
The real swing factor is how one evolving policy and funding backdrop ultimately filters through to long term pricing power and earnings durability.
That earnings durability question is exactly what the full narrative for First Solar unpacks. It highlights where pricing power could be accelerating faster than today’s headline assumptions.
Textron (TXT)
Overview: Textron is a U.S. based industrial and aerospace group that produces aircraft, helicopters, defense systems, specialty vehicles and related financing.
Operations: Textron generates around US$7.6b from Bell and Industrial combined, with most sales coming from the United States at about US$10.7b.
Market Cap: US$13.2b
Textron fits the U.S. Large-Cap Value Equities screen as a long established manufacturer with a U.S. heavy footprint and a modest growth profile that investors often use for more conservative aerospace and industrial exposure.
"The separation of the Industrial segment over the next 12 to 18 months could expose the remaining Aviation, Bell and Systems units to more visible margin pressure if current cost and cash conversion issues persist, which could weigh on segment profit and net margins."
What happens if a single unresolved cost and cash flow pressure point flips from a drag into a cleaner margin story will matter a lot.
If that cost story really is starting to turn, the full narrative for Textron explains how margin pressure today could be masking a cleaner, higher-quality Textron tomorrow.
Exelixis (EXEL)
Overview: Exelixis is a U.S. oncology company that develops and sells targeted cancer medicines, giving this biotech a more value-oriented profile than early stage peers.
Operations: Exelixis generates about US$2.4b from cancer medicines, with roughly US$2.2b from the U.S. and the balance mainly from Europe and Japan.
Market Cap: US$14.4b
Exelixis fits this U.S. Large-Cap Value Equities theme as a profitable cancer drug specialist where an established cash engine funds a growing second franchise.
"The main execution priority is turning CABOMETYX’s current multi billion dollar run rate and the planned zanzalintinib launches in GI and GU oncology into durable, multi franchise cash generation before the cabozantinib patent cliff early in the next decade."
What happens if one carefully managed timing gap between that maturing cash source and the next growth leg proves narrower than current expectations?
If that timing gap is tighter than it looks, the full narrative for Exelixis explains how Exelixis could turn today’s cash engine into an accelerating multi franchise story.
Seeking Alternatives Before Momentum Flies
Fresh ideas move first, and late money often gets caught chasing yesterday’s breakout while better entries keep dropping under the radar for now, get in early.
- Spot income workhorses with staying power by scanning the 6 dividend fortresses to focus on high-yield candidates before everyone else starts crowding in.
- Track AI infrastructure momentum while it still looks under followed by running the 87 AI infrastructure stocks to highlight companies powering the computing backbone behind the headlines.
- Hunt for resilient performers by filtering the 30 resilient stocks with low risk scores designed to surface businesses with sturdier risk profiles before market stress tests them.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com